
Did you read this week’s top infectious disease news coverage from Contagion®?
Kenilworth, New Jersey-based Merck, will take a loss of $0.22 a share from last year’s fourth quarter. This will account for a total loss of $2.9 billion, or $1.9 billion after taxes. The pharmaceutical giant had previously reported a profit of $0.42 a share for that period.
Robert W. Malone, MD, MS, has identified several already-licensed drugs that would be successful in blocking Zika virus replication in human tissues.
Prenatal care for pregnant women with antenatal Zika-related microcephaly needs to be modified to include conversations that include pregnancy options as well as neonatal specialty consultations that will address infant special care needs, economic burden, and other factors.
Carmen D. Zorrilla, MD, professor of obstetrics and gynecology, University of Puerto Rico, School of Medicine, shared her research which aimed to evaluate the growth patterns of fetuses whose mothers acquired Zika virus during pregnancy “and showed no prenatally detectable structural anomalies or maternal conditions that could affect fetal growth.”
Brown University researchers propose thinking about pre-exposure prophylaxis (PrEP) as a nine-step continuum of preventive care, one that improves uptake and focuses on retention in care.
The need for continued surveillance to provide estimates on the rate at which the virus has impacted the incidence of birth defects has prompted the Centers for Disease Control and Prevention (CDC) to award funding to five jurisdictions.
Pedro Fernando de Costa Vasconcelos, MD, PhD, director of the WHO Collaborating Center for Arbovirus and Research, Evandro Chagas Institute, took a closer look at the Zika virus in Brazil during his presentation at The First International Zika Conference.
A decrease in flu activity in the United States brings some relief to a flu season marked by severe illness, but health officials say that the season may last for several more weeks.
Catch up on last month's top infectious disease news coverage from Contagion®.
It is becoming increasingly clear that the hepatitis C virus (HCV) can wreak havoc on a patient’s psychological well-being, even in the absence of a continued viral presence.
A new diagnostics tool to detect Zika was developed to bring easy-to-use technology to remote locations where Zika diagnostics is not readily available.
At The First International Zika Conference, Lenore Pereira, PhD, discussed her research regarding the question of how Zika virus is able to spread from maternal blood to the placenta to reach the fetus.
In a new study, researchers have discovered that Helicobacter pylori, the presence of which is a risk factor for stomach cancer, uses multiple acid sensors to control colonization of the stomach.
Elimination of viral hepatitis depends on individuals actively participating in their own healthcare and management. They can only do this if they understand why and how to protect their miraculous, life-sustaining liver from harm. Education is the key to prevention.
At the First International Zika Conference, Viviane S. Boaventura, MD, PhD, researcher, Fiocruz-Bahia, Gonçalo Moniz Institute, Brazil, presented her research that depicting an association between Congenital Zika Syndrome and hearing loss.
At the First International Zika Conference, Dr. Bogoch, professor of Emergency Medicine at Boston University School of Medicine, chairman at Replikins LLC, Foundation for Research on the Nervous System, explained how Replikins can give advanced warning of outbreaks and their cessation.
The World Health Organization (WHO) recently published, for the first time, a priority list of antibiotic-resistant bacteria that urgently need new antibiotics.
The results of a new study show that taking antibiotics for traveler’s diarrhea could increase the risk of acquiring an extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL) infection.
Members of Doctors Without Borders/Medecins Sans Frontieres discussed the aftermath of the 2014-2015 epidemic in a recent webcast.
At the First International Conference on Zika Virus, Alice Panchaud, PharmD, PhD, clinical pharmacist and pharmacoepidemiologist, CHUV, Lausanne University Hospital, Switzerland, discussed how an international registry can help estimate the risk of Zika virus associated with birth defects and abnormal pregnancy outcomes.
On Friday, February 24, 2017, at the First International Conference on Zika Virus, Matthew Aliota, PhD, discussed the Eliminate Dengue Program.
Both Zika-infected and uninfected pregnant women showed levels of high stress in a recent study conducted in Puerto Rico.
At the First International Conference on Zika Virus, Marta G. Cavalcanti, MD, PhD, discussed her team’s recent research regarding viral RNA shedding in symptomatic and asymptomatic Zika patients who are either mono-infected with Zika or Chikungunya, or co-infected with both.
At the First International Zika Conference, keynote speaker Annelies Wilder-Smith, MD, PhD, DTM&H, MIH, FAMS, FACTM, discussed how Zika has evolved on a global scale.
The results of a new study suggest a 3-7% increase in the likelihood of having a heart attack in some patients with acute respiratory infections also takes nonsteroidal anti-inflammatory drugs (NSAIDs).
The US Food and Drug Administration just announced that it is allowing the marketing of a new test kit for bloodstream infections.
A single dose of the antibiotic oritavancin could save patients and health services time and money when treating acute bacterial skin and skin structure infections (ABSSSIs).
In the first study to examine multiple body fluids for the presence of Zika virus in an ongoing fashion, researchers discover Zika virus remains in bodily fluids longer than other flaviviruses.
New research suggests that human and viral genetics account for one third of the differences in disease progression rates in HIV-positive individuals.